6天皮下葡萄糖依赖性促胰岛素多肽输注对1型糖尿病患者血糖达标时间的影响:随机双盲安慰剂对照交叉试验
该随机双盲安慰剂对照交叉试验在20例1型糖尿病男性中评估6天皮下GIP输注对CGM指标的影响。结果显示GIP未显著改变低血糖时间、高血糖时间、平均血糖或低血糖事件,但显著增加日间严格达标时间(3.9-7.8 mmol/L)11.2±5.1%(95%CI 0.41,21.9,p=0.02)。
要点
- 6天皮下GIP输注未显著改善1型糖尿病男性总体血糖达标时间。
- GIP显著增加日间严格达标时间(3.9-7.8 mmol/L)约2小时/天。
- GIP未改变低血糖时间、高血糖时间、平均血糖或低血糖事件。
核心结论
- 6天皮下GIP输注未对1型糖尿病男性总体血糖达标时间产生确切效果,但使日间严格达标时间增加约2小时/天。
研究设计与样本
- 随机、安慰剂对照、双盲交叉试验,纳入20例男性1型糖尿病患者(18-75岁,稳定胰岛素治疗≥3个月,糖尿病病程2-15年,空腹血浆C肽<200 pmol/l,BMI 20-27 kg/m2,HbA1c<69 mmol/mol[8.5%])。
- 受试者接受两次6天连续皮下输注GIP(6 pmol kg-1 min-1)和安慰剂(生理盐水[154 mmol/l NaCl]),期间设7天洗脱期。
- 主要结局为CGM评估的血糖低于范围时间、范围内时间和高于范围时间。
主要发现
- 夜间或日间低血糖时间(<3.9 mmol/l,p=0.53)或高血糖时间(>10 mmol/l,p=0.32)、平均血糖或CGM评估的低血糖事件均无显著差异。
- GIP未改变自我报告的低血糖或安全性指标。
- 与安慰剂相比,GIP使日间(06:00-23:59)严格达标时间(3.9-7.8 mmol/l)显著增加11.2±5.1%(95%CI 0.41,21.9,p=0.02)。
关键数值与推荐
- 日间严格达标时间(3.9-7.8 mmol/l)增加11.2±5.1%(95%CI 0.41,21.9,p=0.02)。
- 低血糖时间(<3.9 mmol/l)差异p=0.53,高血糖时间(>10 mmol/l)差异p=0.32。
临床怎么用
- GIP输注可能作为辅助手段增加日间严格血糖达标时间,但总体达标时间未改善。
- 需进一步研究确认GIP在1型糖尿病血糖管理中的临床价值。
局限性
- 仅纳入男性患者,结果可能不适用于女性。
- 样本量较小(20例),研究周期短(6天)。
- 未报告低血糖事件的具体数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Type 1 diabetes is characterised by reduced glucagon response to hypoglycaemia, increasing the risk of insulin treatment-associated hypoglycaemia known to hamper glycaemic control. We previously reported a glucagonotropic effect of exogenous glucose-dependent insulinotropic polypeptide (GIP) during insulin-induced hypoglycaemia in individuals with type 1 diabetes. Here we investigate the effect of a 6-day s.c. GIP infusion on time in glycaemic range as assessed by continuous glucose monitoring (CGM) in individuals with type 1 diabetes. METHODS: In a randomised, placebo-controlled, double-blind crossover study, time in glycaemic range (assessed by double-blinded CGM) was evaluated in 20 men with type 1 diabetes (18-75 years, stable insulin treatment ≥3 months, diabetes duration 2-15 years, fasting plasma C-peptide below 200 pmol/l, BMI 20-27 kg/m2, HbA1c <69 mmol/mol [8.5%]) during two × 6 days of continuous s.c. GIP (6 pmol kg-1 min-1) and placebo (saline [154 mmol/l NaCl]) infusion, respectively, with an interposed 7-day washout period. The primary outcome was glycaemic time below range, time in range and time above range. RESULTS: There were no significant differences in time below range (<3.9 mmol/l, p = 0.53) or above range (>10 mmol/l, p = 0.32) during night-time or daytime, in mean glucose, or in hypoglycaemic events as assessed by CGM. GIP altered neither self-reported hypoglycaemia nor safety measures. Compared with placebo, GIP significantly increased time in tight range (3.9-7.8 mmol/l) during daytime (06:00-23:59 hours) by [mean ± SEM] 11.2 ± 5.1% [95% CI 0.41, 21.9] (p = 0.02). CONCLUSIONS/INTERPRETATION: Six-day s.c. GIP infusion in men with type 1 diabetes did not procure convincing effect on overall time in range, but increased time in tight glycaemic range during daytime by ~2 h per day. TRIAL REGISTRATION: ClinicalTrials.gov NCT03734718. FUNDING: The study was funded by grants from The Leona M. and Harry B. Helmsley Charitable Trust and Aase og Ejnar Danielsens Fond.
引用
- Heimbürger SMN, Hoe B, Nielsen CN, et al. The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial. Diabetologia. 2021. PMID: 34405256. doi:10.1007/s00125-021-05547-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。